INA’s response to the spread of COVID-19 (SARS-CoV-2) Novel Coronavirus infections in Japan
With the health safety and security of all stakeholders including employees and customers as our top priority, Ina Research (INA) has been implementing measures based on guidance received from government authorities in order to help prevent the spread of COVID-19 (SARS-CoV-2) infections. COVID-19 is the most urgent social concern in the world. However, comparing with European countries and US or China, the COVID-19 infection overshoot has not appeared in Japan as of today (March 25, 2020). Needless to say, we are never off our guard and protection to maintain all contracted studies in operation and all future studies. Animal Rooms: We, INA has highly advanced technologies such as One-by-One Animal
Information about entering into an agency contract with SAGE HEALTHCARE PTE LTD.
Ina Research Co., Ltd. (hereinafter “the Company”) has decided today to enter into an agency contract with SAGE HEALTHCARE PTE LTD (hereinafter “SAGE”) in Singapore for the purpose of expanding sales of non-clinical studies focusing on pharmaceuticals. Information about entering into an agency contract with SAGE HEALTHCARE PTE LTD. – PDF (132KB)
Announcement concerning the start of agency business with ViruSure
Ina Research Inc. (hereinafter referred to as “our company”) is pleased to announce that our company has decided to start the agency business for ViruSure (Austria : hereinafter referred to as “VS”), which is a contract research organization (hereinafter referred to as “CRO” ) in Japan and Taiwan today. (Please refer to the below PDF file for more details.) Announcement concerning the start of agency business with ViruSure GmbH (PDF: 128KB)